REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID

REGAIN: a randomized controlled clinical trial of oxaloacetate for improving the symptoms of long COVID

BackgroundLong COVID is characterized by fatigue, cognitive dysfunction, and other persistent symptoms. This randomized, double-blind, controlled trial evaluated the efficacy of oral oxaloacetate (OAA) in improving fatigue and cognitive function in adults with long COVID.MethodsA total of 69 partici...

Full description

Saved in:
Bibliographic Details
Main Authors: Suzanne D. Vernon, Candace Rond, Jennifer Bell, Brindisi Butler, Sara Isolampi, Annaleah Otteson, Pearl Phalwane, Samantha Mower, Shad Roundy, David L. Kaufman, Alan B. Cash, Lucinda Bateman
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Neuroscience
Subjects:
oxaloacetate
long COVID
fatigue
cognitive impaiment
randomized clinical trial
Online Access:https://www.frontiersin.org/articles/10.3389/fnins.2025.1627462/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fnins.2025.1627462/full

Similar Items